Draegerwerk Ag & Co. Kgaa · XETR:DRW8

Draegerwerk Ag & Co. Kgaa — Drägerwerk AG & Co. KGaA — Q3 2023 Earnings Presentation

37 slides from Draegerwerk Ag & Co. Kgaa's earnings presentation, November 2023

  1. Slide 1: Capital Markets Presentation

    Capital Markets Presentation Drägerwerk AG & Co. KGaA November 2023, Lübeck Fußzeile: Bitte entsprechende Gesellschaft ergänzen

  2. Slide 2: Disclaimer

    Disclaimer — This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future

  3. Slide 3: Content – Agenda

    Content – Agenda — 01 Company 02 Financials 03 Outlook Drägerwerk AG & Co. KGaA 3

  4. Slide 4: Dräger products protect, support and save lifes

    „Dräger products protect, support and save lifes.“ Stefan Dräger, Chairman of the Executive Board Drägerwerk AG & Co. KGaA 4

  5. Slide 5: Company

    01 Company Drägerwerk AG & Co. KGaA 5

  6. Slide 6: Net sales development – Long-term growth

    Net sales development – Long-term growth Corona pandemic 4.000 Ukraine war 3.500 Debt 3.000 crisis Financial crisis 2.500 Stock- Russian market 2.000 crash financial Mexican crisis 1.500 peso crisis 1.000 500 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2

  7. Slide 7: Dräger worldwide: Net sales, employees, sites

    ~40% ~60% Dräger worldwide Safety Division 20% Medical Division Net sales, employees, sites 3 bn EUR net sales 20221 26% 54% ~59% ~18% Sales, Production, quality, 13% Marketing, logistics, purchasing service 16,219 16% employees ~11% Research 20221 and development Headquarters 70% ~11% Production si

  8. Slide 8: Our markets

    Our markets Hospital Fire Services Oil and gas industry Mining Chemical industry Mehrere Bilder? Drägerwerk AG & Co. KGaA 8

  9. Slide 9: Medical division

    Medical division Operating Room Neonatal Care Intensive Care Hospital wide solutions Anaesthesiology Patient Monitoring & Clinical IT • Anaesthesia • Infinity Acute Care workstations and vaporizers   • System Clincal software • #1 in Europe and solutions #2 in the US market • Telemetry and IT-  

  10. Slide 10: Safety division

    Safety division Chemical Oil & Gas Mining Fire Service Other Markets Breathing Systems Impairment Check Equipment • Self-contained • Alcohol- and drug Breathing Appartus for fire fighters      • screening devices Interlock devices • #2 worldwide and • #1 worldwide and #1 in Europe  #1 in Europ

  11. Slide 11: Medical and safety technology providing long-term growth prospects

    Medical and safety technology providing long-term growth prospects Medical division Safety division • Average expected annual market growth for the global • Very diversified markets with numerous product and medical equipment market significantly exceeding service offerings Attractive growth prospec

  12. Slide 12: Technology and innovation leadership to drive profitable growth

    Technology and innovation leadership to drive profitable growth Strong R&D focus Innovation to enhance future growth (examples) • Approximately 1,800 employees in R&D around the globe. • EUR ~344 million spent for R&D activities in 2022.* • Very close collaboration with customers to develop new and

  13. Slide 13: Exploit growth potentials in developing countries

    Exploit growth potentials in developing countries • Focus on the specific needs of customer in developing countries Investments in profitable • Capitalize on the significant investments into the Sales & Service infrastructure and specific growth in developing market knowledge, especially in our Regi

  14. Slide 14: Service- and consumables business a clear focus of our sales activities

    Service- and consumables business a clear focus of our sales activities Further expansion of • Capitalize on large installed base to expand after sales business service and consumables • Focus on combined sale of equipment and after sales contracts business • Expansion of disposable consumables busi

  15. Slide 15: Financials

    02 Financials Drägerwerk AG & Co. KGaA 15

  16. Slide 16: Business development Dräger Group – 5-year view

    Business development Dräger Group – 5-year view Dräger Group 2018 2019 2020 2021 2022 9M 2023 9M 2022 € million € million € million € million € million € million € million Net sales 2,595 2,781 3,406 3,328 3,045 2,321 2,027 Change (nominal) 0.9% 7.2% 22.5% -2.3% -8.5% 14.5 -15.6% Change (net of curr

  17. Slide 17: Key figures Dräger Group – 5-year view

    Key figures Dräger Group – 5-year view Dräger Group 2018 2019 2020 2021 2022 9M 2023 9M 2022 Change € million € million € million € million € million € million € million % Cashflow (from operating activities) 4 164 460 385 -144 47 -279 >+100 Investments 78 121 178 194 131 96 90 6.7 Cash and cash equ

  18. Slide 18: Outlook

    03 Outlook Drägerwerk AG & Co. KGaA 18

  19. Slide 19: Guidance: Expectations for fiscal year 2023

    Guidance Expectations for fiscal year 2023 Results achieved Forecast for Current forecast Indicator for fiscal year 2022 fiscal year 2023 (last published) Net sales (net of currency effects) -11.5% 7.0 to 11.0% Upper end Gross margin 40.7% 43.0 to 45.0% Confirmed EBIT margin -2.9% 0.0 to 3.0% 2.0 to

  20. Slide 20: Technology for Life

    Technology for Life Drager

  21. Slide 21: Guidance: Expectations for fiscal year 2023

    Guidance Expectations for fiscal year 2023 Results achieved Forecast for Current forecast Indicator for fiscal year 2022 fiscal year 2023 (last published) Net sales (net of currency effects) -11.5% 7.0 to 11.0% Upper end Gross margin 40.7% 43.0 to 45.0% Confirmed EBIT margin -2.9% 0.0 to 3.0% 2.0 to

  22. Slide 22: Executive Board of Drägerwerk Verwaltungs AG

    Executive Board of Drägerwerk Verwaltungs AG Bild Stefan Dräger Gert-Hartwig Lescow Rainer Klug Dr. Reiner Piske Anton Schrofner Chairman of the Deputy Chairman of Executive Board Executive Board Executive Board Executive Board ‒ the Executive Board; member for Safety member for Sales & member for M

  23. Slide 23: Dräger shares – Shareholder structure

    Dräger shares Shareholder structure 10,160,000 Common shares (28.4% Free float) 8,600,000 Preferred shares (100.0% Free float) USA Germany Free float 34% 7% 28.38% Great Britain 5% France Shareholding 5% Shareholder structure 2 Common shares 1 Norway 4% Rest of Europe 6% Dräger family Private invest

  24. Slide 24: Business development Group / Division / Region

    Business development Group / Division / Region Dräger Group 2018 2019 2020 2021 2022 9M 2023 9M 2022 Change Change € million € million € million € million € million € million € million % nominal % fx-adjusted Medical division 1,643.0 1,741.8 2,302.2 2,064.2 1,821.5 1,359.2 1,208.3 12.5 15.2 Safety d

  25. Slide 25: Medical division Business development – 5-year view

    Medical division Business development – 5-year view Medical division 2018 2019 2020 2021 2022 9M 2023 9M 2022 Change Change € million € million € million € million € million € million € million % nominal % fx-adjusted Net sales 1,643.0 1,741.8 2,302.2 2,064.2 1,821.5 1,359.2 1,208.3 12.5 15.2 Europe

  26. Slide 26: Safety division Business development – 5-year view

    Safety division Business development – 5-year view Safety division 2018 2019 2020 2021 2022 9M 2023 9M 2022 Change Change € million € million € million € million € million € million € million % nominal % fx-adjusted Net sales 952.0 1,039.1 1,104.1 1,264.2 1,223.7 961.7 818.7 17.5 19.9 Europe 598.4 6

  27. Slide 27: Functional expenses Group 5-year view

    Functional expenses Group 5-year view Dräger Group 2018 2019 2020 2021 2022 9M 2023 9M 2022 Change € million € million € million € million € million € million € million % R&D -252.2 -263.7 -289.6 -328.6 -343.5 -247.5 -252.1 -1.8 % of net sales -9.7% -9.5% -8.5% -9.9% -11.3% -10.7 -12.4 Sales & Marke

  28. Slide 28: Cash flow statement Group 5-year view

    Cash flow statement Group 5-year view Dräger Group 2018 2019 2020 2021 2022 9M 2023 9M 2022 Change € million € million € million € million € million € million € million % Group net profit 34.9 33.8 249.9 154.3 -63.6 47.1 -112.7 >+100 Change in inventories -76.9 -24.5 -162.0 14.4 -81.8 -99.3 -156.0 -

  29. Slide 29: Balance sheet (assets) Group 12M

    Balance sheet (assets) Group 12M Assets 31.12.2022 31.12.2021 Change € million € million % Intangible assets 350.6 354.1 -1.0 Property, plant and equipment (incl. Right-of-use-assets) 587.9 597.0 -1.5 Other noncurrent assets 265.4 235.4 12.7 Noncurrent assets 1,203.9 1,186.6 1.5 Inventories 697.0 61

  30. Slide 30: Balance sheet (equity and liabilities) Group 12M

    Balance sheet (equity and liabilities) Group 12M Equity and liabilities 31.12.2022 31.12.2021 Change € million € million % Equity 1,319.4 1,260.5 4.7 Provisions for pensions and similar obligations 202.9 357.9 -43.3 Noncurrent personnel provisions 34.7 37.1 -6.4 Noncurrent interest bearing loans 62.

  31. Slide 31: Simplification of the capital structure: Termination of participation certificates (1 of 2)

    Simplification of the capital structure (2020-2023) Termination of participation certificates (1 of 2) Distributable result 32% 100% Participation certificates Common & preferred shares Series A, series K, series D 5 Securities 2 Securities 68% Common & preferred shares Drägerwerk AG & Co. KGaA 31

  32. Slide 32: Simplification of the capital structure: Termination of participation certificates (2 of 2)

    Simplification of the capital structure (2020-2023) Termination of participation certificates (2 of 2) Termination of participation certificates Earnings per share Pro forma as of December 2020, assuming full In 2020, all 831,951 outstanding participation certificates were cancelled. distribution an

  33. Slide 33: Innovation share

    Innovation share Share in medical 1 in % 45 New products Upgrades 41% 40 37% 36% 35 30% 30 28% 26% 25 24% 20% 32% 20 32% 25% 23% 15 21% 10 18% 15% 5 5% 5% 4% 5% 2% 3% 0 2016 2017 2018 2019 2020 2021 2022 1 Launched in the last 3 years; products are regarded as new, if they enable Dräger to either en

  34. Slide 34: Sustainability Ratings

    Sustainability Ratings • In 2022, Dräger was again awarded the ›Prime Label‹ in the ESG Corporate Rating by ISS and thus the best rating in the ›Health Care Equipment & Suppliers‹ sector. • In the CSR assessment by the EcoVadis Institute, Dräger was among the top one percent of the industry in 2022

  35. Slide 35: Financial calendar

    Financial calendar Events Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January. March 7, 2024 Annual Report 2023 Conference Call April 25, 2024 Report for the first three months 2024 Confe

  36. Slide 36: Contact

    Contact Thomas Fischler | Head of Treasury & Investor Relations Moislinger Alle 53-55 23558 Lübeck, Germany Tel. +49 451 882 2685 Mail: thomas.fischler@draeger.com Nikolaus Hammerschmidt | Investor Relations Manager Moislinger Alle 53-55 23558 Lübeck, Germany Tel. +49 451 882 8903 Mail: nikolaus.ham

  37. Slide 37: Thank you

    Thank you Drägerwerk AG & Co. KGaA 37

Drägerwerk AG & Co. KGaA — Q3 2023 Earnings Presentation on 6ix